Editas Medicine, Inc.
EDIT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.14 | -0.22 | -0.21 |
| FCF Yield | -209.54% | -17.79% | -29.79% | -9.57% |
| EV / EBITDA | -0.03 | -4.18 | -2.33 | -8.60 |
| Quality | ||||
| ROIC | -81.36% | -36.77% | -43.97% | -28.52% |
| Gross Margin | 82.02% | 92.24% | 67.85% | 80.22% |
| Cash Conversion Ratio | 0.89 | 0.86 | 0.80 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | 17.91% | 45.15% | -39.88% | 7.55% |
| Free Cash Flow Growth | -60.05% | 24.56% | -5.64% | 8.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.53 | 0.44 | 0.94 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.07 | 0.00 |
| Cash Conversion Cycle | -161.41 | -450.13 | -5,814.77 | -360.97 |